The purpose of this study is to investigate the effects of oral administration of probiotics on the metabolism of uremic toxins, in the patients with End Stage Renal Disease (ESRD). One hundred and fifty hemodialysis patients are recruited, and a Double Blind Randomized Parallel Controlled Trial was performed.The microbiota-derived uremic toxin, such as indoxyl sulfate and p-cresol sulfate, are measured as Primary Outcome. The Fecal microbiome, fecal metabolites, blood metabolites, defecation, Gastrointestinal Symptoms The Kidney Disease Quality of Life and The Occurrence of Cardiovascular Event are also assessed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
150
Daily take 4.0E+10 CFU of probiotics
Beijing Anzhen Hospital
Beijing, China
General Hospital of Chinese Armed Police Forces
Beijing, China
Peking University Aerospace Centre Hospital
Beijing, China
Changes in Microbiota-derived uremic toxin
follow up the patients at Month 0, 3, 6
Time frame: 6 months
Changes in Fecal Microbiome
follow up the patients at Month 0, 3, 6
Time frame: 6 months
Changes in Fecal metabolites
follow up the patients at Month 0, 3, 6
Time frame: 6 months
Changes in Blood metabolites
follow up the patients at Month 0, 3, 6
Time frame: 6 months
Defecation questionnaire
follow up the patients at Month 0, 3, 6
Time frame: 6 months
Gastrointestinal Symptoms
follow up the patients at Month 0, 3, 6
Time frame: 6 months
The Kidney Disease Quality of Life
follow up the patients at Month 0, 3, 6
Time frame: 6 months
The Occurrence of Cardiovascular Event
Time frame: 6 month follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.